Elizabeth H.z. Thompson - 30 Dec 2022 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role
EVP, Research & Development
Signature
/s/ Patrick McIlvenny, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
30 Dec 2022
Net transactions value
-$1,075,296
Form type
4
Filing time
04 Jan 2023, 15:18:21 UTC
Previous filing
20 Jul 2022
Next filing
06 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Options Exercise +19,055 +273% 26,024 30 Dec 2022 Direct F1
transaction HZNP Ordinary Shares Tax liability $1,075,296 -9,449 -36% $113.80 16,575 30 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Restricted Stock Units (RSU) Options Exercise $0 -7,257 -100% $0.000000* 0 30 Dec 2022 Ordinary Shares 7,257 Direct F1, F2
transaction HZNP Restricted Stock Units (RSU) Options Exercise $0 -4,657 -50% $0.000000 4,657 30 Dec 2022 Ordinary Shares 4,657 Direct F1, F3
transaction HZNP Restricted Stock Units (RSU) Options Exercise $0 -7,141 -33% $0.000000 14,283 30 Dec 2022 Ordinary Shares 7,141 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each RSU represents a contingent right to receive one ordinary share of the Issuer.
F2 The final tranche of ordinary shares subject to the RSU vested on December 30, 2022.
F3 The remaining ordinary shares subject to the RSU vest on January 5, 2024.
F4 The remaining ordinary shares subject to the RSU vest ratably on January 5, 2024 and January 5, 2025.